Cuenca Cuenca J I, Borrego Dorado I, Vázquez Albertino R, Gómez Camarero P, Sanz Viedma S, Fernández López R
Unidad Diagnóstica de Gestión de Medicina Nuclear, Hospitales Universitarios Virgen del Rocío, Sevilla, España.
Rev Esp Med Nucl. 2008 Nov-Dec;27(6):411-7.
To evaluate the efficacy and clinical impact of FDG-PET in patients with suspected recurrent ovarian cancer.
Between October 2001 and October 2006, we retrospectively studied 49 FDG-PET performed in 40 women (age: 52.4 +/- 12.2 years) with ovarian cancer, who had suspicion of recurrent disease by positive morphologic imaging tests (MIT) or increased tumour markers and negative MIT. All patients underwent whole body FDG-PET after the injection of 370-434 MBq of (18)FDG. The results were confirmed by histology in 31 cases, and by clinical-radiological follow-up in 18.
Prevalence of disease was 79.6 %. We obtained a global sensitivity and positive predictive value of 87.2 % and 87.2 %, and an accuracy of 79.6 %. Results led to a change in the patient's management in 25 cases (51 %). Subgroup results were: Sensitivity of 81.8 % in patients with increased tumour markers and negative MIT, and 89.3 % in patients with operable malignant lesions.
FDG-PET has high sensitivity and clinical impact in patients with suspicion of recurrent ovarian cancer. Better results were obtained in patients with increased tumour markers and negative MIT.
评估氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）在疑似复发性卵巢癌患者中的疗效及临床影响。
在2001年10月至2006年10月期间，我们对40名女性（年龄：52.4±12.2岁）进行了回顾性研究，这些女性患有卵巢癌，通过阳性形态学成像检查（MIT）或肿瘤标志物升高且MIT阴性怀疑疾病复发。所有患者在注射370 - 434MBq的（18）FDG后接受全身FDG-PET检查。31例结果经组织学证实，18例经临床放射学随访证实。
疾病患病率为79.6%。我们获得的总体敏感性和阳性预测值为87.2%，准确性为79.6%。结果导致25例（51%）患者的治疗方案发生改变。亚组结果为：肿瘤标志物升高且MIT阴性的患者敏感性为81.8%，可手术恶性病变患者的敏感性为89.3%。
FDG-PET在疑似复发性卵巢癌患者中具有高敏感性和临床影响。肿瘤标志物升高且MIT阴性的患者取得了更好的结果。
